SH2D3A and infection: In order to test the antiviral efficacy of our SARS-CoV-2 DsiRNA swarms against Omicron variants, the chosen DsiRNA swarms targeting 3′-UTR, NSP1, and NSP2, as well as chimeric SARS-CoV-2 swarm, were pre-transfected into cells, followed by an infection with two prevalent Omicron variants (BQ.1.1 and XBB.1.5) identified in 2022 and 2023, respectively.